PI3K/AKT/mTOR pathway

PI3K/AKT/mTOR pathway
Name	PI3K/AKT/mTOR pathway
Caption	Schematic representation of a conserved intracellular signaling cascade
Organism	Homo sapiens
Function	Regulation of cell growth, proliferation, survival, metabolism, and autophagy

PI3K/AKT/mTOR pathway The PI3K/AKT/mTOR pathway is a conserved intracellular signaling cascade that transduces extracellular cues into coordinated control of cellular growth, metabolism, survival, and autophagy. Discovered through convergent work in signal transduction and cancer biology, the cascade integrates inputs from receptor tyrosine kinases, G protein-coupled receptors, and nutrient-sensing machinery to regulate downstream effectors influencing cell cycle and protein synthesis.

Overview

The canonical cascade links phosphoinositide 3-kinases to serine/threonine kinase AKT and the mechanistic target of rapamycin, forming a central node integrating growth factor signals from receptors such as those studied by James Watson, Francis Crick, J. Michael Bishop, Harold Varmus and laboratories at institutions like Cold Spring Harbor Laboratory, Broad Institute, Salk Institute, Dana-Farber Cancer Institute and Memorial Sloan Kettering Cancer Center. Historical advances intersect with work by researchers affiliated with National Institutes of Health, Stanford University, Massachusetts Institute of Technology, University of California, San Francisco, and pharmaceutical developments at GlaxoSmithKline, Pfizer, Novartis, AstraZeneca, and Roche. Foundational methods from groups linked to Max Planck Society, Howard Hughes Medical Institute, Yale University, Harvard Medical School, and Cambridge University accelerated characterization of pathway components.

Components and Molecular Mechanism

Core enzymatic components include class I PI3K catalytic and regulatory subunits identified in studies at Imperial College London, University College London, University of Oxford, and University of Cambridge; AKT isoforms AKT1, AKT2, AKT3 characterized by teams at Johns Hopkins University and University of Pennsylvania; and mTOR complexes mTORC1 and mTORC2 elucidated with contributions from University of Toronto, University of California, San Diego, Scripps Research, and Cold Spring Harbor Laboratory. Upstream activators include receptor families such as EGFR (researched at Memorial Sloan Kettering Cancer Center), IGF1R (studied at National Cancer Institute), PDGFR (investigated at Karolinska Institutet), and GPCRs examined at Columbia University and Yale University School of Medicine. Lipid second messengers such as PIP3 are produced by PI3K and opposed by PTEN, first described in studies tied to University of Chicago and University of Michigan. Downstream effectors encompass TSC1/TSC2 complexes, Rheb GTPase, and translational regulators S6K and 4E-BP1, with mechanistic insights from laboratories at École Normale Supérieure, Institut Pasteur, Weizmann Institute of Science, and Max Delbrück Center.

Regulation and Feedback Loops

Regulatory inputs include phosphatases such as PTEN and PHLPP, ubiquitin ligases characterized at ETH Zurich and Karolinska Institutet, and adaptor proteins detailed in work at University of Illinois, University of Texas MD Anderson Cancer Center, and Vanderbilt University. Negative and positive feedback loops involve S6K-mediated IRS phosphorylation (studied at University of Birmingham), mTORC2 regulation of AKT activation (described by teams at University of Basel and University of Freiburg), and cross-talk with MAPK pathway nodes investigated at Institut Curie, CNRS, Riken, and RIKEN Center for Biosystems Dynamics Research. Nutrient sensing communicates through AMPK (research advanced at University of Cambridge and University of Edinburgh) and Rag GTPases (characterized by groups at University of Geneva and University of California, Berkeley), while hypoxia-responsive regulation links to HIF1α studies from Duke University and University of Washington.

Physiological Roles and Cellular Functions

Physiological roles include control of metabolic homeostasis examined in cohorts at University of Copenhagen, Karolinska Institutet, University of Helsinki, and Monash University; roles in neuronal function investigated at University College London Institute of Neurology, University of Oxford Nuffield Department of Clinical Neurosciences, and Max Planck Institute for Brain Research; and immune cell regulation studied at Emory University, La Jolla Institute for Immunology, Trudeau Institute, and Ragon Institute. Developmental and stem cell functions have been delineated in work at St. Jude Children’s Research Hospital, Children’s Hospital of Philadelphia, Cold Spring Harbor Laboratory, and Institute of Molecular Biology (Austria). Autophagy and lysosomal biogenesis links derive from studies at Nanyang Technological University and University of Melbourne.

Dysregulation in Disease and Oncogenesis

Aberrant activation via mutations, amplifications, or loss of regulatory genes contributes to oncogenesis documented in clinical series from Memorial Sloan Kettering Cancer Center, Mayo Clinic, Cleveland Clinic, Johns Hopkins Hospital, and MD Anderson Cancer Center. Frequently mutated loci include PIK3CA, PTEN, and AKT isoforms observed in tumor profiling consortia such as The Cancer Genome Atlas, International Cancer Genome Consortium, and initiatives at European Molecular Biology Laboratory. Dysregulation is implicated in metabolic disorders investigated by Joslin Diabetes Center and cardiovascular pathologies studied at Mount Sinai Hospital, Cedars-Sinai Medical Center, and RUSH University Medical Center. Neurodegenerative associations are explored at Massachusetts General Hospital, Karolinska University Hospital, and UCLH. Viral and infectious modulation of the cascade has been reported in research from Centers for Disease Control and Prevention, World Health Organization, and virology groups at University of Oxford and Pasteur Institute.

Therapeutic Targeting and Inhibitors

Therapeutic strategies include small-molecule inhibitors and biologics developed by industry partners such as Novartis, AstraZeneca, Pfizer, Roche, Bristol-Myers Squibb, Merck & Co., Eli Lilly and Company, Sanofi, and GlaxoSmithKline. Representative agents target PI3K isoforms, AKT, and mTOR complexes with landmark compounds investigated in clinical trials at centers including Dana-Farber Cancer Institute, Royal Marsden Hospital, Gustave Roussy, National Cancer Center Hospital (Japan), and Peter MacCallum Cancer Centre. Combination regimens couple inhibitors with chemotherapies or targeted agents evaluated in consortia like European Organisation for Research and Treatment of Cancer and National Comprehensive Cancer Network. Resistance mechanisms and biomarker development are the focus of translational programs at Translational Genomics Research Institute, Fred Hutchinson Cancer Research Center, Barcelona Clinic Cancer Center, and Siteman Cancer Center.

Category:Signal transduction